All trials
NCT07505095NOT YET RECRUITING

Efficacy of Lecanemab at Different Therapeutic Doses for Alzheimer's Disease (AD) in Real-World Practice

✨ Plain-English version on the way · ~2 days

We're still translating this one. In a couple of days, you'll see what this trial actually tests — and whether it matters for APOE4 carriers like you. For now, here's the sponsor's own description:

This study will analyze the clinical indicators, imaging data, and serum biomarkers of Alzheimer's disease (AD) patients receiving different doses of the medication before and after treatment. It aims to clarify whether the therapeutic efficacy in the low-dose group is equivalent to that in the recommended-dose group, and meanwhile to determine the optimal dose range for effective pharmacotherapy.
Read full record on ClinicalTrials.gov

Eligibility check — Phoenix members

Phoenix members see for THIS trial:

  • APOE genotype match
  • Cognitive status fits inclusion
  • Specific exclusions flagged
  • Distance to nearest site
Check my eligibility — become a member
Sites
1 location
Start
2026-04-30

Interventions tested

  • DRUGLecanemab 10 mg/kg
  • DRUGLecanemab 5-10mg/kg
View full record on ClinicalTrials.gov

We use cookies to enhance your experience.